Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Assets Average (2018 - 2025)

Denali Therapeutics (DNLI) has disclosed Assets Average for 8 consecutive years, with $1.1 billion as the latest value for Q3 2025.

  • On a quarterly basis, Assets Average fell 24.85% to $1.1 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $1.1 billion, a 24.85% decrease, with the full-year FY2024 number at $1.3 billion, down 3.29% from a year prior.
  • Assets Average was $1.1 billion for Q3 2025 at Denali Therapeutics, down from $1.2 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.6 billion in Q1 2021 to a low of $1.1 billion in Q3 2025.
  • A 5-year average of $1.4 billion and a median of $1.4 billion in 2022 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: skyrocketed 152.35% in 2021, then fell 24.85% in 2025.
  • Denali Therapeutics' Assets Average stood at $1.4 billion in 2021, then dropped by 5.83% to $1.3 billion in 2022, then decreased by 11.06% to $1.2 billion in 2023, then rose by 18.3% to $1.4 billion in 2024, then decreased by 21.44% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Assets Average are $1.1 billion (Q3 2025), $1.2 billion (Q2 2025), and $1.3 billion (Q1 2025).